- Home
- LCNB vs CUE Comparison
LCNB vs CUE Comparison
Compare LCNB & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LCNB | CUE |
|---|---|---|
| Founded | 1877 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.1M | 233.5M |
| IPO Year | 1999 | 2017 |
Fundamental Metrics
Financial Performance| Metric | LCNB | CUE |
|---|---|---|
| Price | $19.39 | $26.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 39.0K | ★ 195.5K |
| Earning Date | 04-22-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.43% | N/A |
| EPS Growth | ★ 68.04 | 61.11 |
| EPS | ★ 0.84 | N/A |
| Revenue | $6,445,000.00 | ★ $27,466,000.00 |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | $23.18 | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $14.31 | $0.17 |
| 52 Week High | $21.32 | $45.50 |
Technical Indicators
Market Signals| Indicator | LCNB | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 39.64 |
| Support Level | $19.25 | $0.24 |
| Resistance Level | $20.62 | $33.95 |
| Average True Range (ATR) | 0.45 | 3.26 |
| MACD | -0.13 | -0.62 |
| Stochastic Oscillator | 25.93 | 7.22 |
Price Performance
Historical ComparisonAbout LCNB LCNB Corporation
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.